NY-ESO-1 TCR-T cell therapy
/ Gilead
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 16, 2023
Phase I TCR Trial Experience Targeting HPV-16-Driven Tumors
(IO-SUMMIT EUROPE 2023)
- "However, durable responses are still elusive. Recent translational data point to various mechanisms of treatment resistance employed by the tumor in context of TCR-engineered T cell therapy."
P1 data • Oncology
1 to 1
Of
1
Go to page
1